Peptide Suppliers: AI Visibility Market Discovery Index

Benchmark Summary

Questions This Section Answers

• Which peptide supplier leads AI recommendation coverage, and by how much?
• Which brands moved beyond normal month-to-month variation since the July 2026 baseline?

In October 2026, Phoenix Pharmaceuticals leads the category with a valid recommendation coverage of 35.0%, ahead of Core Peptides at 29.3%, a gap of 5.7 percentage points. Phoenix Pharmaceuticals and Core Peptides traded the coverage lead across the series, and both returned to higher levels this month after a September 2026 dip.

The largest coverage increase since baseline was AminoVault, rising to 18.9% in October 2026 from 12.0% in July 2026. The largest coverage decline since baseline was Phoenix Pharmaceuticals, easing to 35.0% in October 2026 from 38.3% in July 2026, a move within normal month-to-month variation across the full series.

This was a month of movement. AminoVault and Blue Sky Peptide rose beyond normal month-to-month variation since July 2026. Several brands that had declined through September 2026 recovered sharply in October 2026: Core Peptides rose 14.2 points from September 2026, Phoenix Pharmaceuticals rose 16.4 points, and Biotech Peptides rose 6.4 points, each a significant prior-month move. The benchmark began with 489 prompt-surface observations in October 2026 and produced 297 qualified observations after qualification.

Current Benchmark at a Glance

Qualified surface breadth refers to the number of canonical AI surface families, among the six tested (ChatGPT, Copilot, Gemini, Perplexity, AI Overviews, and AI Mode), that produced at least one qualified observation. Both months registered all six families. The August 2026 and September 2026 intermediate months also registered all six families.

For the strategic interpretation of this benchmark, read CiteWorks Studio's analysis of How AI Search Is Recommending Peptide Suppliers

Research Scope and Qualification

Questions This Section Answers

• How many prompt-surface observations qualified for the public peptide suppliers benchmark?
• Why do brand-level percentages use qualified observations instead of the raw collection?

The public benchmark is narrower than the raw collection universe by design. The funnel below shows how observations were qualified.

Brand-level percentages use the qualified observations as the public denominator, not the raw collection. See the AI Market Discovery Methodology for details.

Current Brand Standings

Questions This Section Answers

• How do the tracked peptide suppliers rank by valid recommendation coverage?
• Which brands appear most often in the top three or as the single top recommendation?

This table is the primary current-month benchmark view, sorted by valid recommendation coverage.

How to Read the Standings

• Presence rate: the share of qualified observations in which the brand is mentioned at all, regardless of recommendation status.
• Valid recommendation coverage: the share of qualified observations in which the brand receives a valid recommendation, the primary benchmark metric.
• Top-three rate: the share of qualified observations in which the brand appears among the top three recommended options.
• Rank-one rate: the share of qualified observations in which the brand is the single top recommendation.
• Net sentiment: the balance of positive over negative mentions, scaled from 0 to 1.

For formulas and denominator rules, see AI Market Discovery Metric Definitions.

Recommendation Coverage Movement

Questions This Section Answers

• Which peptide supplier posted the largest coverage gain since the July 2026 baseline?
• What does Phoenix Pharmaceuticals' coverage decline alongside rising top-three and rank-one rates indicate?

Largest Increase: AminoVault

AminoVault's valid recommendation coverage rose 6.9 percentage points to 18.9% in October 2026, up from 12.0% in July 2026, a rise beyond normal month-to-month variation. The increase came on a broad base, with presence rate up 7.8 points to 20.2% and top-three rate up 8.5 points to 16.2%, while rank-one rate rose 1.6 points to 7.4%.

Largest Decline: Phoenix Pharmaceuticals

Phoenix Pharmaceuticals' valid recommendation coverage eased 3.3 percentage points to 35.0% in October 2026, down from 38.3% in July 2026, a move within normal month-to-month variation across the full series. The brand nevertheless leads the category on coverage. Its presence rate fell 9.0 points to 51.2% since July 2026, while its top-three rate (up 5.6 points to 28.6%) and rank-one rate (up 4.5 points to 12.5%) both rose, indicating a shift toward more prominent, less scattered placement.

Category Leader: Phoenix Pharmaceuticals

Phoenix Pharmaceuticals remains the category leader in valid recommendation coverage at 35.0% in October 2026, ahead of Core Peptides at 29.3%. Its top-three rate of 28.6% and rank-one rate of 12.5% are both the highest in the category. After declining to 18.6% in September 2026, the brand recorded a 16.4-point prior-month rise, a significant move beyond normal variation.

Other Movements

Blue Sky Peptide rose 6.3 percentage points to 6.7% in October 2026 from 0.4% in July 2026, beyond normal variation, and has increased in each of the three months since July 2026, though its top-three and rank-one rates remain near or at zero. Core Peptides and Biotech Peptides were classified as stable across the full series but each rose significantly from the prior month: Core Peptides up 14.2 points and Biotech Peptides up 6.4 points. Peptide Tech and Peptides Source remained at minimal coverage, at 0.3% each in October 2026.

Recommendation Placement Snapshot

Questions This Section Answers

• Why can similar coverage levels still hide different first-position rates among peptide suppliers?

Coverage alone does not show how prominently a brand is recommended. Among the leading brands, placement patterns differ notably.

Close coverage levels can still hide different first-position rates. Core Peptides' 29.3% coverage is paired with a 6.1% rank-one rate, while AminoVault's 18.9% coverage is paired with a higher 7.4% rank-one rate.

Buyer-Intent Distribution

All qualified observations in each month fell into the Brand Recommendation class of buyer intent.

The current public series measures brand recommendation discovery specifically and does not yet contain qualified observations in pricing or multi-brand comparison queries.

Historical Measurement Record

Questions This Section Answers

• Does the four-month series support a trend, or only month-to-month movement?
• How did the coverage leader's level change across the measurement record?

This is an evergreen benchmark URL. New measurements are added to the same report.

Evidence and Source Layer

Questions This Section Answers

• What does source presence tell us about the information environment behind AI recommendations?
• Does a cited source prove it caused the recommendation?

The benchmark is built from prompt-level observations that retain the query, AI/search surface, answer, brand outcome, recommendation placement, sentiment, and, where exposed, citations or attributable evidence sources. Source presence is evidence about the information environment. It is not automatically proof that the source caused the recommendation.

Scope Boundaries

This public benchmark does not measure the following:

• Market share or attributable sales
• Every possible AI response to a given query
• Organic-search ranking positions
• Social media mention volume
• Private or sponsored channels
• Causality from a metric movement alone

Top 10 Cited Domains

Questions This Section Answers

• Which domains do AI platforms cite most often for peptide supplier answers?
• Which tracked brand-owned domains appear among the most-cited sources?

Across all AI platform responses in October 2026, the benchmark recorded 3,446 citations spanning 966 unique domains. The most-cited sources were concentrated among a mix of general platforms, brand-owned sites, and community destinations.

Citations are moderately distributed rather than concentrated in a single source, with the top domain accounting for 4.3% and the tenth-ranked domain 1.5%. Two tracked brands' own domains appear among the most-cited sources: phoenixpeptide.com (Phoenix Pharmaceuticals) at rank 2 and aminovault.com (AminoVault) at rank 7. The list is otherwise led by broad platforms and community or media destinations such as google.com, youtube.com, reddit.com, and instagram.com, alongside several supplier and commerce domains, indicating that AI answers in this vertical draw on a blend of official brand sites, third-party media, and community discussion.

About This Benchmark

The LLM Authority Index AI Market Discovery Index tracks how often and how prominently brands appear in AI-generated answers across the major AI and search surfaces. This is a neutral industry benchmark; every tracked brand is treated on its own terms.

• AI Market Discovery Methodology
• AI Market Discovery Metric Definitions
• AI Market Discovery Research Standards
• Modeled AI Authority Value

Get a Company-Level Authority Index

The public industry benchmark shows category-level standings. A company-level Authority Index can go deeper.

Get my free AI Company Index